1. Academic Validation
  2. Transcriptional analysis of antiviral small molecule therapeutics as agonists of the RLR pathway

Transcriptional analysis of antiviral small molecule therapeutics as agonists of the RLR pathway

  • Genom Data. 2016 Feb 1;7:290-2. doi: 10.1016/j.gdata.2016.01.020.
R R Green 1 C Wilkins 1 S Pattabhi 2 R Dong 1 Y Loo 1 M Gale Jr 1
Affiliations

Affiliations

  • 1 Department of Immunology, and the Center for Innate Immunity and Immune Disease (CIIID), University of Washington, Seattle, WA, USA.
  • 2 Department of Global Health, University of Washington, Seattle, WA, USA.
Abstract

The recognition of pathogen associated molecular patterns (PAMPs) by Pattern Recognition Receptors (PRR) during viral Infection initiates the induction of Antiviral signaling pathways, including activation of the Interferon Regulator Factor 3 (IRF3). We identified small molecule compounds that activate IRF3 through MAVS, thereby inhibiting Infection by viruses of the families Flaviviridae (West Nile virus, dengue virus and hepatitis C virus), Filoviridae (Ebola virus), Orthomyxoviridae (influenza A virus), Arenaviridae (Lassa virus) and Paramyxoviridae (respiratory syncytial virus, Nipah virus) (1). In this study, we tested a lead compound along with medicinal chemistry-derived analogs to compare the gene transcriptional profiles induced by these molecules to that of other known MAVS-dependent IRF3 agonists. Transcriptional analysis of these small molecules revealed the induction of specific Antiviral genes and identified a novel module of host driven immune regulated genes that suppress Infection of a range of RNA viruses. Microarray data can be found in Gene Expression Omnibus (GSE74047).

Keywords

Anti-viral; IRF-3; Immunity; Innate; RIG-I.

Figures
Products